NCT01386359

Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant

Evaluating Nulojix Long-Term Safety in Transplant

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 914 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To describe how Nulojix (belatacept) is used and to determine how often Post-Transplant Lymphoproliferative Disorder (PTLD), Central Nervous System (CNS) PTLD and Progressive Multifocal Leukoencephalopathy (PML), rare and serious complications of transplant treatment, occur in patients taking Nulojix (belatacept) in a real-world setting.

Detailed description

Time Perspective: Prospective for the majority of patients who are enrolled at the time they begin Nulojix (belatacept) treatment. Retrospective for any patients receiving Nulojix (belatacept) prior to enrollment into ENLiST Registry

Conditions

• Kidney Transplantation

Interventions

Type	Name	Description
DRUG	No Intervention	No Intervention. Subjects are previously treated with Nulojix (belatacept)

Timeline

• Start date: 2012-02-29
• Primary completion: 2019-04-30
• Completion: 2019-04-30
• First posted: 2011-07-01
• Last updated: 2022-06-06

Locations

36 sites across 1 country: United States